Format

Send to

Choose Destination
Exp Oncol. 2010 Sep;32(3):172-80.

The role of UDP-glucuronosyltransferases and drug transporters in breast cancer drug resistance.

Author information

1
Division of Biochemical Toxicology, National Center for Toxicological Research, Jefferson, AR 72079, USA. athena.starlarddavenport@fda.hhs.gov

Abstract

One of the major limitations of chemotherapy is that often, over time, tumor cells become either inherently resistant or develop multidrug resistance to the treatment. Another limitation of chemotherapy is toxicity to normal tissues and adverse side effects. The reasons for the failure of some cancers to respond to chemotherapeutic drugs are not clear but have been attributed to alterations in many molecular pathways, which include drug metabolizing enzymes and drug transporter genes. Alterations in the energy-dependent ATP-binding cassette (ABC) transporter genes have been suggested to confer a drug-resistant phenotype by decreasing the intracellular accumulation of chemotherapeutic drugs via efflux mechanisms. In addition, polymorphisms in UDP-glucuronosyltransferases (UGTs) have been reported to correlate with clinical outcome and drug resistance. In this review, we provide an overview of known polymorphisms within UGTs and ABC transporter genes that have been reported to have altered expression and/or activity in breast cancer. Those polymorphic variants that affect the clinical efficacy and confer drug resistance of chemotherapeutic agents, including hormonal therapies, taxanes, anthracyclines, and alkylating agents, in breast cancer.

PMID:
21403613
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for MORION LLC
Loading ...
Support Center